Prostate cancer study on race and drug response pulled before starting
NCT ID NCT06527690
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study aimed to see if a person's race changes how well a combination of two drugs (niraparib and abiraterone acetate plus prednisone) works for a certain type of advanced prostate cancer. It planned to enroll Black, Hispanic, White, and Native American men whose cancer had specific DNA repair problems. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.